Loading...
XSTO
IMMU
Market cap40mUSD
, Last price  
SEK
Name

Mendus AB (publ)

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-9.53%
Rev. gr., 5y
-21.25%
Revenues
5m
-82.28%
005,000000000016,670,00006,0002,995,00028,487,0005,048,000
Net income
-128m
L+26.35%
-2,287,294-2,670,303-2,629,325-6,887,974-16,175,036-35,614,623-43,922,885-73,587,834-80,337,643-97,860,000-135,708,000-92,469,000-136,694,000-136,991,000-101,619,000-128,399,000
CFO
-80m
L-51.05%
-1,666,198-3,233,502-7,146,028-9,280,851-40,102,127-40,228,602-33,738,195-46,446,815-104,670,000-145,808,000-56,626,000-138,033,000-109,331,000-162,761,000-79,671,000
Earnings
Aug 21, 2025

Profile

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
URL
https://mendus.com/
IPO date
Apr 22, 2013
Employees
30
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑06
Income
Revenues
5,048
-82.28%
28,487
851.15%
2,995
49,816.67%
Cost of revenue
135,145
129,704
140,773
Unusual Expense (Income)
NOPBT
(130,097)
(101,217)
(137,778)
NOPBT Margin
Operating Taxes
(1,794)
Tax Rate
NOPAT
(130,097)
(101,217)
(135,984)
Net income
(128,399)
26.35%
(101,619)
-25.82%
(136,991)
0.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
69,141
321,793
BB yield
Debt
Debt current
2,745
2,523
31,611
Long-term debt
40,969
45,603
72,670
Deferred revenue
Other long-term liabilities
850
(1,000)
Net debt
(58,191)
(72,656)
61,813
Cash flow
Cash from operating activities
(79,671)
(162,761)
(109,331)
CAPEX
(1,835)
(1,823)
(12,097)
Cash from investing activities
(1,577)
(442)
(12,324)
Cash from financing activities
61,515
242,097
8,194
FCF
(86,311)
(138,025)
(170,980)
Balance
Cash
101,905
120,782
41,850
Long term investments
618
Excess cash
101,653
119,358
42,318
Stockholders' equity
(805,643)
(690,031)
(616,015)
Invested Capital
1,473,499
1,419,246
1,206,645
ROIC
ROCE
EV
Common stock shares outstanding
48,636
23,128
216,488
Price
Market cap
EV
EBITDA
(123,598)
(94,914)
(132,930)
EV/EBITDA
Interest
3,115
5,264
Interest/NOPBT